Eric K. Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, posted on X:
“MARIPOSA study update: Combination therapy shows over ONE-YEAR mOS improvement compared to osimertinib alone.
Key data to discuss with patients in clinic—but does this simplify first-line treatment decisions?”
Dr. Eric K. Singhi is a thoracic and head and neck medical oncologist, currently serving as an Assistant Professor in the Department of General Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX.